Analysis of arrhythmogenic profile in a canine model of chronic atrioventricular block by comparing in vitro effects of the class III antiarrhythmic drug nifekalant on the ventricular action potential indices between normal heart and atrioventricular block heart

Journal of Pharmacological Sciences

Volumn 103, Issue 2, 2007, Pages 181-188

  Takahara, Akira ^a   Nakamura, Hideki ^b   Nouchi, Hideaki ^b   Tamura, Takeshi ^b   Tanaka, Toshikazu ^b   Shimada, Hideaki ^b   Tamura, Miku ^b   Tsuruoka, Noriko ^b   Takeda, Kentaro ^b   Tanaka, Hikaru ^b   Shigenobu, Koki ^b   Hashimoto, Keitaro ^a   Sugiyama, Atsushi ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b TOHO UNIVERSITY   (Japan)

Author keywords

Action potential; Chronic atrioventricular block dog; Nifekalant

Indexed keywords

ANTIARRHYTHMIC AGENT; NIFEKALANT;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARRHYTHMOGENESIS; ARTICLE; ATRIOVENTRICULAR BLOCK; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; HEART DEPOLARIZATION; HEART VENTRICLE CONTRACTION; IN VITRO STUDY; NONHUMAN; PURKINJE CELL; SINUS RHYTHM;

EID: 33847172353     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0061077     Document Type: Article

References (26)

1. Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci. 2003;24:619-625.
2. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, et al. Independent Academic Task Force. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol. 2004;15:475-495.
3. Thomsen MB, Matz J, Volders PG, Vos MA. Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias. Pharmacol Ther. 2006;112:150-170.
4. The ICH Steering Committee. The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (S7B). The international conference on harmonization of technical requirements for registration of pharmaceuticals for human use (ICH). The Guideline was recommended for adoption at Step 4 of the ICH process in May 2005 (http:/ /www.ich.org/ ).
5. Belardinelli L, Shryock JC, Wu L, Song Y. Use of preclinical assays to predict risk of drug-induced torsades de pointes. Heart Rhythm. 2005;2(2 Suppl):S16-S22.
6. Vos MA, de Groot SH, Verduyn SC, van der Zande J, Leunissen HD, Cleutjens JP, et al. Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation. 1998;98:1125-1135.
7. Sugiyama A, Ishida Y, Satoh Y, Aoki S, Hori M, Akie Y, et al. Electrophysiological, anatomical and histological remodeling of the heart to AV block enhances susceptibility to arrhythmogenic effects of QT-prolonging drugs. Jpn J Pharmacol. 2002;88:341-350.
8. Yoshida H, Sugiyama A, Satoh Y, Ishida Y, Yoneyama M, Kugiyama K, et al. Comparison of the in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug, sematilide, using a canine chronic atrioventricular block model. Circ J. 2002;66:758-762.
9. Satoh Y, Sugiyama A, Takahara A, Chiba K, Hashimoto K. Electropharmacological and proarrhythmic effects of a class III antiarrhythmic drug nifekalant hydrochloride assessed using the in vivo canine models. J Cardiovasc Pharmacol. 2004;43:715-723.
10. Thomsen MB, Verduyn SC, Stengl M, Beekman JD, de Pater G, van Opstal J, et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation. 2004;110:2453-2459.
11. 1 blocker terfenadine-induced torsades de pointes arrhythmias. Br J Pharmacol. 2006;147:634-641.
12. + currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes. Circulation. 1999;100:2455-2461.
13. Cavero I, Crumb W. ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis. Expert Opin Drug Saf. 2005;4:509-530.
14. Nakaya H, Tohse N, Takeda Y, Kanno M. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol. 1993;109:157-163.
15. Akie Y, Ni C, Aye NN, Xue YX, Hashimoto K. Proarrhythmic effects of four class III antiarrhythmic drugs, MS-551, sematilide, dofetilide and KCB328, examined using ambulatory ECG. Asia Pacific J Pharmacol. 2000;14:101-109.
16. Brennan M, Palaniswami M, Kamen P. Do existing measures of Poincaré plot geometry reflect nonlinear features of heart rate variability? IEEE Trans Biomed Eng. 2001;48:1342-1347.
17. Schneider J, Hauser R, Andreas JO, Linz K, Jahnel U. Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs. Eur J Pharmacol. 2005;512:53-60.
18. Abi-Gerges N, Small BG, Lawrence CL, Hammond TG, Valentin JP, Pollard CE. Evidence for gender differences in electrophysiological properties of canine Purkinje fibres. Br J Pharmacol. 2004;142:1255-1264.
19. Biliczki P, Acsai K, Virag L, Talosi L, Jost N, Biliczki A, et al. Cellular electrophysiological effect of terikalant in the dog heart. Eur J Pharmacol. 2005;510:161-166.
20. Igawa M, Aonuma K, Okamoto Y, Hiroe M, Hiraoka M, Isobe M. Anti-arrhythmic efficacy of nifekalant hydrochloride, a pure class III anti-arrhythmic agent, in patients with healed myocardial infarction and inducible sustained ventricular tachycardia. J Cardiovasc Pharmacol. 2002;40:735-742.
21. Volders PG, Sipido KR, Vos MA, Kulcsar A, Verduyn SC, Wellens HJ. Cellular basis of biventricular hypertrophy and arrhythmogenesis in dogs with chronic complete atrioventricular block and acquired torsade de pointes. Circulation. 1998;98:1136-1147.
22. Sipido KR, Volders PG, de Groot SH, Verdonck F, Van de Werf F, Wellens HJ, et al. Enhanced Ca2+ release and Na/Ca exchange activity in hypertrophied canine ventricular myocytes: potential link between contractile adaptation and arrhythmogenesis. Circulation. 2000;102:2137-2144.
23. Biliczki P, Virag L, Iost N, Papp JG, Varro A. Interaction of different potassium channels in cardiac repolarization in dog ventricular preparations: role of repolarization reserve. Br J Pharmacol. 2002;137:361-368.
24. Jost N, Virag L, Bitay M, Takacs J, Lengyel C, Biliczki P, et al. Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle. Circulation. 2005;112:1392-1399.
25. Roden DM. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol. 1998;21:1029-1034.
26. 2+ channel blocker cilnidipine assessed in the chronic atrioventricular conduction block dogs. J Pharmacol Sci. 2004;96:219-223.